Compass Therapeutics, INC 10-Q quarterly reports

Compass Therapeutics reports increased R&D and G&A expenses in Q2 2026, alongside promising but mixed clinical trial results for its lead candidate, tovecimig.

Compass Therapeutics reports increased R&D spending and a net loss for Q1 2026, but positive topline results for tovecimig in biliary tract cancer.

Compass Therapeutics reported increased net losses in Q3 2025 but bolstered its financial position with a $129.3 million capital raise, extending its cash runway into 2028.

Compass Therapeutics reported an increased net loss for Q2 2025, driven by higher R&D expenses, and announced a delay in the overall survival analysis for its lead tovecimig Phase 2/3 study.

Compass Therapeutics' tovecimig, in combination with paclitaxel, achieved a statistically significant improvement in overall response rate in second-line biliary tract cancer patients, and the first patient was dosed in a front-line investigator-sponsored trial.

Compass Therapeutics reported its Q3 2024 financial results and provided updates on its clinical development programs, including discontinuing a Phase 2 trial for CTX-009 and planning a new trial.

Compass Therapeutics reported a net loss of $13.1 million for the second quarter of 2024, while advancing its clinical programs and securing a key milestone payment.

Compass Therapeutics reported a net loss of $10.8 million for the first quarter of 2024, while progressing its clinical-stage oncology programs.